Key result
Androgen deprivation therapy is not associated with increased cerebral infarction risk in prostate cancer.
Why the study?
Previous studies have reported conflicting results regarding the association between androgen deprivation therapy and cerebral infarction in prostate cancer patients.
Does androgen deprivation therapy increase the risk of cerebral infarction in patients with prostate cancer?
Cohort (n=36,146)
Does androgen deprivation therapy increase the risk of cerebral infarction in patients with prostate cancer?
Hazard Ratio: 1.045 (95% CI 0.943–1.159)
Absolute Event Rate: 14.9% vs 14.6%
p-value: p=0.401
Androgen deprivation therapy is not associated with an increased risk of cerebral infarction in patients with prostate cancer after adjusting for potential confounders.
ADT showed no association with cerebral infarction after propensity matching; leaves open residual confounding in prior conflicting reports.
PURPOSE: Previous studies have suggested that androgen deprivation therapy (ADT) is associated with cerebral infarction. However, conflicting results have been reported by other researchers. The aim of this study was to evaluate the association between ADT and cerebral infarction in patients with prostate cancer (PC) using big data. MATERIALS AND METHODS: Using information from the National Health Insurance Service database representative of the entire Korean adult PC population (n = 206 735), data regarding ADT and cerebral infarction between 2009 and 2016 were analyzed. Adjusted hazard ratios for cerebral infarction associated with ADT were estimated using propensity score-matched Cox proportional hazards models and Kaplan-Meier survival analyses. RESULTS: The final cohort comprised 36 146 individuals with PC, including 24 069 men (66.6%) who underwent ADT. During the mean follow-up of 4.1 years, 2792 patients were newly diagnosed with cerebral infarction. In the unmatched cohort, there was a significant difference in the annual incidence of cerebral infarction between the ADT and non-ADT groups (22.8 vs 14.6 per 1000 person-years, respectively). However, there was no significant difference between the ADT and non-ADT groups in the matched cohort (14.9 vs 14.6 per 1000 person-years). The adjusted hazard ratio for cerebral infarction for PC patients who underwent ADT was 1.045 (95% CI 0.943-1.159; P = 0.401) compared with those who did not undergo ADT. In addition, the cumulative duration of ADT was also not associated with an increased risk for cerebral infarction. However, older age, hypertension, diabetes, myocardial infarction, congestive heart failure, peripheral vascular disease, renal disease, dementia, and atrial fibrillation were revealed to be factors contributing to cerebral infarction. CONCLUSION: This nationwide population-based study revealed that ADT was not associated with cerebral infarction after adjusting for potential confounders.
No takes yet. Share an insight, caveat, or question.
Tae et al. (2019) conducted a cohort in Prostate cancer (n=36,146). Androgen deprivation therapy (ADT) vs. No ADT was evaluated on Cerebral infarction (HR 1.045, 95% CI 0.943-1.159, p=0.401). Androgen deprivation therapy was not associated with an increased risk of cerebral infarction in patients with prostate cancer (HR 1.045; 95% CI 0.943-1.159; P=0.401).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: